Posted by Michael Wonder on 06 Jul 2022
InflaRx receives FDA fast track designation for treatment of ulcerative pyoderma gangrenosum
6 July 2022 - Fast track follows recently reported orphan drug designation by both US FDA and EMA
InflaRx today announced that the US FDA granted a fast track designation to the development of its first-in-class anti-C5a monoclonal antibody vilobelimab for the treatment of ulcerative pyoderma gangrenosum.
